Athersys, Inc. (ATHX)
(Delayed Data from NSDQ)
$1.55 USD
+0.04 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.55 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.55 USD
+0.04 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.55 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Athersys (ATHX) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
What Makes Athersys (ATHX) a New Buy Stock
by Zacks Equity Research
Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.
Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study
by Zacks Equity Research
Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.
Athersys (ATHX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7%
by Zacks Equity Research
Audentes Therapeutics (BOLD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Alnylam Files Clinical Trial Application for ALN-AAT02 in UK
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) submits a Clinical Trial Authorization application in the U.K. to start a phase I/II study on its early stage candidate, ALN-AAT02, for treating alpha-1 liver disease.
Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo
by Zacks Equity Research
Amgen (AMGN) gains an FDA approval for its sNDA with respect to a once-weekly dosing option of its multiple myeloma drug Kyprolis (70 mg/m2) combined with dexamethasone (Kd).
Medicines Company to Continue Inclisiran Studies as Planned
by Zacks Equity Research
The Medicines Company (MDCO) gets Independent Data Monitoring Committee's recommendation to continue late-stage inclisiran studies as planned and designed.
The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion
IPOs and Foreign Investment Propel Biotech: 4 Top Picks
by Nitish Marwah
A steady influx of foreign as well as domestic investments in U.S. biotech has gone a long way in boosting gains for the space.
Is Athersys (ATHX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ATHX) Outperforming Other Medical Stocks This Year?
4 Biotech Stocks to Bet on in the Second Half of 2018
by Ekta Bagri
While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.
Athersys Enters Oversold Territory
by Zacks Equity Research
Athersys Enters Oversold Territory
Top Ranked Momentum Stocks to Buy for June 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 12th:
The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals
"Right To Try" Brings Good News for Biotech Sector: 5 Picks
by Gourav Kanti Bagchi
Passage of the Right To Try law and WHO's focus on assessing the quality of bio-similar drugs is expected to benefit biotech stocks.
5 Biotech Stocks to Boost Your Portfolio's Health This Year
by Kinjel Shah
Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio.
BioMarin's Palynziq Gets FDA Approval for Phenylketonuria
by Zacks Equity Research
BioMarin's (BMRN) enzyme therapy, Palynziq (pegvaliase) gets approval for the treatment of phenylketonuria in adult patients.
INSYS Gets Negative FDA Recommendation for Pain Candidate
by Zacks Equity Research
INSYS Therapeutics' (INSY) NDA for buprenorphine sublingual spray fails to get recommendation for approval for treating moderate-to-severe acute pain after bunionectomy from FDA advisory committee.
Moving Average Crossover Alert: Athersys, Inc. (ATHX)
by Zacks Equity Research
Moving Average Crossover Alert: Athersys, Inc. (ATHX)
Athersys (ATHX) in Focus: Stock Moves 7.2% Higher
by Zacks Equity Research
Athersys (ATHX) shares rose more than 7% in the last trading session, amid huge volumes.
Athersys (ATHX) in Focus: Stock Moves 10.22% Higher
by Zacks Equity Research
Athersys (ATHX) was a big mover last session, as the company saw its shares rise more than 10% on the day.
Why Athersys, Inc. (ATHX) Could Be Positioned for a Surge
by Zacks Equity Research
Athersys, Inc. (ATHX) seems to Be Positioned for a Surge on the back of its favorable zacks rank and solid estimate revisions.
Can the Rally in Athersys (ATHX) Shares Continue?
by Zacks Equity Research
Athersys, Inc. (ATHX) has been on the move lately as the stock has risen by 62.4% in the past four weeks, and it is currently trading well above its 20-Day SMA